Across TCGA pan-cancer cohorts, TMEM179B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TMEM179B data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher TMEM179B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM179B expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

GBM, LSCC, and LUAD are the cancer types where TMEM179B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.376	0.664	.001	19	view →
LSCC	DFS	Median	III,IV	1.000	0.565	.002	16	view →
LUAD	OS	Tertile	III,IV	1.000	0.667	.033	10	view →
HNSC	OS	Quartile	IV	0.700	1.000	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: TMEM179B tumor-vs-normal RNA expression · all TMEM179B data types